| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/21/2005 | US20050159457 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors |
| 07/21/2005 | US20050159445 Selective iGluR5 receptor antagonists |
| 07/21/2005 | US20050159441 Active ingredient and solvent can be stored separately until apparatus is used in a nebuliser; propellant-free; active ingredient is present in highly-concentrated form for storage purposes; inhalers |
| 07/21/2005 | US20050159439 Management of postoperative pain |
| 07/21/2005 | US20050159435 [3-Methyl-4-(pyridin-3-yloxy)-phenyl]-(6-piperidin-3-ylethynyl-quinazolin-4-yl)-amine; selective inhibitors of receptor tyrosine kinases and non-receptor tyrosine kinases (eg: Ick, src, abl) or serine/threonine kinases (e.g.: cyclin dependent kinases); carcinoma |
| 07/21/2005 | US20050159434 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl)-3-oxo-propionitrile mono citrate salt; immunosuppressants, autoimmune diseases, skin disorders, Crohn's disease, antidiabetic agents, anticancer agents, antiarthritic agents |
| 07/21/2005 | US20050159426 Novartis drug called Imatinib, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, methanosulfonate; synergistic mixture with a second antineoplastic agent |
| 07/21/2005 | US20050159425 Inducing tolerance to an antigen by administering to patient a prostaglandin or agonist thereof, a phosphodiesterase inhibitor, and antigen or a derivative thereof; suppressing immune system or an inflammatory response; for example, use of misoprostol and rolipram; antiinflammatory agents, antiallergens |
| 07/21/2005 | US20050159422 Inhibitors of akt activity |
| 07/21/2005 | US20050159420 Disruption of signal transduction by inhibition of kinases in target cells |
| 07/21/2005 | US20050159414 Inflammatory and obstructive respiratory complaints such as asthma or Chronic obstructive pulmonary disease (COPD); reduced side effects; |
| 07/21/2005 | US20050159403 Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage |
| 07/21/2005 | US20050159396 Compositions and methods of treatment for inflammatory diseases |
| 07/21/2005 | US20050159395 Topical applying to skins; skin disorders; anticarcinogenic agents |
| 07/21/2005 | US20050159388 Non-nucleotide compositions and method for inhibiting platelet aggregation |
| 07/21/2005 | US20050159387 Combination of ATP-depleting agents (mitochondrial ATP-inhibitor, a methylthioadenosine phosphorylase inhibitor or an inhibitor of De Novo purine synthesis); chemotherapy |
| 07/21/2005 | US20050159373 Novel polypeptides, and nucleic acids encoding the same |
| 07/21/2005 | US20050159370 6-11 Bicyclic ketolide derivatives |
| 07/21/2005 | US20050159367 Treatment of DNA viral infections |
| 07/21/2005 | US20050159361 Luteinizing hormone releasing hormone receptor agonist/antagonist (leuprorelin) and steroidal androgen receptor agonist (dehydroepiandrosterone, testosterone); sustained release |
| 07/21/2005 | US20050159347 Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase |
| 07/21/2005 | US20050159337 Use of botulinum toxin therapy for treatment of overactive bladder |
| 07/21/2005 | US20050159333 Carbachol, neurokinin A, P2X receptor antagonist, electrical stimulus, to inhibit polypeptide in Rho associated kinase pathway; lower urinary tract disorders, overactive bladder |
| 07/21/2005 | US20050159332 Ntb-a,a a surface molecule involved in natural killer cellss activity |
| 07/21/2005 | US20050158800 Detecting the expression of a G-protein coupled receptor, identifying agonists or antagonists of the receptor |
| 07/21/2005 | US20050158778 Transcription factor for use in generating immoglobulin for prevention and treatment of fungal infection |
| 07/21/2005 | US20050158771 Using gene expression patterns and skeletal muscle marker as diagnostic tool in detection and prognostication of obesity |
| 07/21/2005 | US20050158726 Compositons and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene |
| 07/21/2005 | US20050158724 Methods, of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| 07/21/2005 | US20050158709 Determining effect of human serum protein on viricidal agents; bioassay; enzyme inhibitors; plasma protein binding and drug efficacy; drug screening and pharmacokinetics |
| 07/21/2005 | US20050158404 Composition and method for treatment of acne |
| 07/21/2005 | US20050158401 Associated with decreased nitric oxide bioavailability; using an arginine- and/or arginase-inhibitor based therapy; asthma, sickle cell disease, and pulmonary hypertension |
| 07/21/2005 | US20050158382 Hydrocodone and acetaminophen; twice-a-day administration; pain relievers |
| 07/21/2005 | US20050158348 Eutectic mixture of camphor, menthol, thymol and similar compounds is a powerful solvent for non-steroidal anti-inflammatory drugs; transdermal drug delivery of e.g. indomethacin, diclofenac, or ketoprofen |
| 07/21/2005 | US20050158325 Comprises imidazonaphthyridine amine, oxazoloquinoline amine, thiazoloquinoline amine, oxazolopyridine amine, thiazolopyridine amine, oxazolonaphthyridine amine, or thiazolonaphthyridine amine derivatives |
| 07/21/2005 | US20050158294 isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals; preventing urinary tract ailments in companion animals; reducing levels of pathogenic Clostridia, Escherichia, Salmonella bacteria in the faeces |
| 07/21/2005 | US20050158293 Canine probiotic Lactobacilli |
| 07/21/2005 | US20050158290 Process for the preparation of a nutrient formulation |
| 07/21/2005 | US20050158288 Methods of organ regeneration |
| 07/21/2005 | US20050158275 Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 07/21/2005 | US20050158251 Oral composition of solvent, an oxidant and alkyl cellulose in varnish form |
| 07/21/2005 | DE19901683B4 Analgetikum mit kontrollierter Wirkstofffreisetzung Analgesic with controlled release of active ingredient |
| 07/21/2005 | DE10359790A1 Brausezubereitung einer basischen arzneilich wirksamen Substanz Effervescent formulation of a basic biological active substance |
| 07/21/2005 | CA2592631A1 Compositions and methods to treat recurrent medical conditions |
| 07/21/2005 | CA2553211A1 Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer |
| 07/21/2005 | CA2552632A1 Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer |
| 07/21/2005 | CA2552411A1 Pharmaceutical compositions comprising an extract of euphorbia prostrata |
| 07/21/2005 | CA2548179A1 Methods and compositions for the production of monoclonal antibodies |
| 07/20/2005 | EP1555032A1 Medicinal composition for treating arteriosclerosis |
| 07/20/2005 | EP1555030A1 Sustained release preparation for treating coronary stenosis or obstruction |
| 07/20/2005 | EP1555025A2 Use of dehydroepiandrosterone analogs for the treatment of asthma |
| 07/20/2005 | EP1555021A1 Combinations of a mevalonate pathway inhibitor and a PPAR-gamma agonist for treating cancer |
| 07/20/2005 | EP1555020A2 Benzimidazole derivatives as modulators IgE |
| 07/20/2005 | EP1555019A1 Pharmacologic drug combination in vagal-induced asystole |
| 07/20/2005 | EP1555008A1 Tooth bleaching composition |
| 07/20/2005 | EP1554586A2 Screening method |
| 07/20/2005 | EP1554572A2 Compositions and methods for modulating blood-brain barrier transport |
| 07/20/2005 | EP1554393A2 P27 prevents cellular migration |
| 07/20/2005 | EP1554371A2 Prebiotic and preservative uses of oil-emulsified probiotic encapsulations |
| 07/20/2005 | EP1554315A1 Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
| 07/20/2005 | EP1554281A2 Process for preparing certain pyrrolotriazine compounds |
| 07/20/2005 | EP1553982A2 METHODS AND COMPOSITIONS FOR MODULATING T HELPER (T sb H /sb ) CELL DEVELOPMENT AND FUNCTION |
| 07/20/2005 | EP1553981A1 Bacterial transforming agent |
| 07/20/2005 | EP1553974A1 Pharmaceutical composition comprising carriers for products |
| 07/20/2005 | EP1553967A1 Use of amide derivative of ge 2270 factor a3 for the treatment of acne |
| 07/20/2005 | EP1553965A2 Method of treating tumors |
| 07/20/2005 | EP1553964A2 Ketoamide inhibitors in chronic nerve disease |
| 07/20/2005 | EP1553962A1 Combination chemotherapy with chlorotoxin |
| 07/20/2005 | EP1553960A1 Neuregulin based methods and compositions for treating cardiovascular diseases |
| 07/20/2005 | EP1553955A2 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| 07/20/2005 | EP1553954A2 Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
| 07/20/2005 | EP1553951A2 Methods of using and compositions comprising a jnk inhibitor for the treatment, prevention, management and/or modification of pain |
| 07/20/2005 | EP1553950A1 Therapeutic treatment |
| 07/20/2005 | EP1553942A1 Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent |
| 07/20/2005 | EP1553941A1 Lisinopril/lercanidipine combination therapy |
| 07/20/2005 | EP1553939A1 Epothilone derivatives for the treatment of multiple myeloma |
| 07/20/2005 | EP1553934A1 Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
| 07/20/2005 | EP1553932A2 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| 07/20/2005 | EP1553931A1 Compounds, compositions, and methods |
| 07/20/2005 | EP1553922A1 Salmeterol superfine formulation |
| 07/20/2005 | EP1553912A1 Compositions and methods for the diagnosis and treatment of tumor |
| 07/20/2005 | EP1553909A2 Quick dissolve compositions and tablets based thereon |
| 07/20/2005 | EP1553893A2 Implantation of encapsulated biological materials for treating diseases |
| 07/20/2005 | EP1553831A2 Process for screening fungitoxic compounds |
| 07/20/2005 | EP1472251B1 Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals |
| 07/20/2005 | EP1317309B1 Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant |
| 07/20/2005 | EP1299348A4 Compounds and compositions for delivering active agents |
| 07/20/2005 | EP1286673B8 Ligands of integrin receptors |
| 07/20/2005 | EP1229965B1 Placental human neurokinin b precursor |
| 07/20/2005 | EP1152757B1 Mmp inhibitors in connective tissue softening |
| 07/20/2005 | EP1011648B2 Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer |
| 07/20/2005 | EP0977586B1 Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| 07/20/2005 | EP0910571B1 Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
| 07/20/2005 | EP0759939B1 Methods and compositions for the dry powder formulation of interferons |
| 07/20/2005 | EP0703785B1 Methods for treating muscle diseases and disorders |
| 07/20/2005 | CN1643134A Method for producing pseudo islets |
| 07/20/2005 | CN1642974A Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of NS3 (hepatitis C) |
| 07/20/2005 | CN1642973A A method for treating allergies |
| 07/20/2005 | CN1642971A A nucleic acid encoding a G-protein-coupled receptor, and uses thereof |
| 07/20/2005 | CN1642968A A human ribonucleotide reductase M2 subunit |